218 related articles for article (PubMed ID: 22374980)
1. Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells.
Tang S; Moore ML; Grayson JM; Dubey P
Cancer Res; 2012 Apr; 72(8):1975-85. PubMed ID: 22374980
[TBL] [Abstract][Full Text] [Related]
2. In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.
Akins EJ; Moore ML; Tang S; Willingham MC; Tooze JA; Dubey P
Cancer Res; 2010 May; 70(9):3473-82. PubMed ID: 20406970
[TBL] [Abstract][Full Text] [Related]
3. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
4. Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.
Olson BM; Jankowska-Gan E; Becker JT; Vignali DA; Burlingham WJ; McNeel DG
J Immunol; 2012 Dec; 189(12):5590-601. PubMed ID: 23152566
[TBL] [Abstract][Full Text] [Related]
5. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma.
Goforth R; Salem AK; Zhu X; Miles S; Zhang XQ; Lee JH; Sandler AD
Cancer Immunol Immunother; 2009 Apr; 58(4):517-30. PubMed ID: 18719913
[TBL] [Abstract][Full Text] [Related]
6. CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis.
McNally A; Hill GR; Sparwasser T; Thomas R; Steptoe RJ
Proc Natl Acad Sci U S A; 2011 May; 108(18):7529-34. PubMed ID: 21502514
[TBL] [Abstract][Full Text] [Related]
7. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
[TBL] [Abstract][Full Text] [Related]
8. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
Kiniwa Y; Miyahara Y; Wang HY; Peng W; Peng G; Wheeler TM; Thompson TC; Old LJ; Wang RF
Clin Cancer Res; 2007 Dec; 13(23):6947-58. PubMed ID: 18056169
[TBL] [Abstract][Full Text] [Related]
9. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.
Simons BW; Cannella F; Rowley DT; Viscidi RP
Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503
[TBL] [Abstract][Full Text] [Related]
10. Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization.
Koh YT; Gray A; Higgins SA; Hubby B; Kast WM
Prostate; 2009 May; 69(6):571-84. PubMed ID: 19143030
[TBL] [Abstract][Full Text] [Related]
11. YB-1 immunization combined with regulatory T-cell depletion induces specific T-cell responses that protect against neuroblastoma in the early stage.
Zheng J; Liu P; Yang X
Acta Biochim Biophys Sin (Shanghai); 2012 Dec; 44(12):1006-14. PubMed ID: 23169344
[TBL] [Abstract][Full Text] [Related]
12. Disruption of CD8+ Treg activity results in expansion of T follicular helper cells and enhanced antitumor immunity.
Alvarez Arias DA; Kim HJ; Zhou P; Holderried TA; Wang X; Dranoff G; Cantor H
Cancer Immunol Res; 2014 Mar; 2(3):207-16. PubMed ID: 24778317
[TBL] [Abstract][Full Text] [Related]
13. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
Shen L; Ciesielski M; Ramakrishnan S; Miles KM; Ellis L; Sotomayor P; Shrikant P; Fenstermaker R; Pili R
PLoS One; 2012; 7(1):e30815. PubMed ID: 22303460
[TBL] [Abstract][Full Text] [Related]
14. Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells.
Muthuswamy R; Corman JM; Dahl K; Chatta GS; Kalinski P
Prostate; 2016 Sep; 76(12):1095-105. PubMed ID: 27199259
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
[TBL] [Abstract][Full Text] [Related]
16. B7 blockade alters the balance between regulatory T cells and tumor-reactive T cells for immunotherapy of cancer.
Zhou P; Zheng X; Zhang H; Liu Y; Zheng P
Clin Cancer Res; 2009 Feb; 15(3):960-70. PubMed ID: 19188167
[TBL] [Abstract][Full Text] [Related]
17. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
Redmond WL; Linch SN; Kasiewicz MJ
Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
[TBL] [Abstract][Full Text] [Related]
18. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.
Hanson HL; Kang SS; Norian LA; Matsui K; O'Mara LA; Allen PM
J Immunol; 2004 Apr; 172(7):4215-24. PubMed ID: 15034034
[TBL] [Abstract][Full Text] [Related]
19. Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responses.
Chen YL; Chang MC; Chen CA; Lin HW; Cheng WF; Chien CL
PLoS One; 2012; 7(10):e47190. PubMed ID: 23082146
[TBL] [Abstract][Full Text] [Related]
20. Mesothelin virus-like particle immunization controls pancreatic cancer growth through CD8+ T cell induction and reduction in the frequency of CD4+ foxp3+ ICOS- regulatory T cells.
Zhang S; Yong LK; Li D; Cubas R; Chen C; Yao Q
PLoS One; 2013; 8(7):e68303. PubMed ID: 23874581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
